Global Launch of ExactechGPS® Gains Early Surgeon Acceptance

GAINESVILLE, Fla.

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder and spine, reported today that surgeons around the world are expressing positive response to Exactech’s (Nasdaq: EXAC) international launch of ExactechGPS^® Guided Personalized Surgery, a computer-assisted technology that provides surgeons with real-time, patient-specific data to guide their implantation and alignment of Exactech’s Optetrak Logic^® knee system.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150910006300/en/

ExactechGPS® Guided Personalized Surgery is a powerful, yet compact advanced surgical technology platform that delivers efficiency and reproducibility in total joint replacement. (Photo: Business Wire)

Nearly 40 orthopaedic surgeons from eight countries, including China, Japan, Singapore, Malaysia, India, U.S., Australia and South Korea, convened this month for Exactech’s first Asia-Pacific computer-assisted surgery masters course in Singapore. The event featured lectures from renowned surgeons and technology thought leaders, and provided surgeons hands-on cadaveric experience with the technology. A similar medical education course in Taiwan drew 35 surgeons.

“Accurate surgery leads to better benefit for patients and this system has a high potential for becoming widely used in Japan,” said Kentaro Suzuki, MD, head of orthopaedic surgery at Iida Hospital, Nagao, Japan.

Suzuki is among the growing list of surgeon users around the world, who are expressing even greater confidence in the proper placement of implants through use of ExactechGPS. The continued development of the system follows Exactech’s recent acquisition of technology partner Blue Ortho, a leading computer-assisted surgery development and manufacturing firm.

Exactech introduced ExactechGPS^® to surgeons in the U.S. in 2014, and has since broadened its reach by providing medical education and supporting surgeries in more than 11 countries. The technology has steadily gained market acceptance and worldwide reach.

Exactech CEO David Petty said, “Surgeons and hospitals around the world are recognizing the clinical advantages of using ExactechGPS^® for their knee replacement patients. The positive response from surgeons in varied parts of the globe is a testament to the technology’s unmatched capabilities and Exactech’s commitment to deliver innovative solutions that improve clinical outcomes.”

About ExactechGPS^®

ExactechGPS^® Guided Personalized Surgery is a powerful, yet compact advanced surgical technology platform that delivers efficiency and reproducibility in total joint replacement. Merging sophisticated technology with innovative instrumentation, ExactechGPS delivers a real-time, patient-specific solution designed for improved clinical outcomes. For more information about ExactechGPS^®, visit www.exactechgps.com.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at http://www.exac.com. Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at http://www.exac.com and http://www.hawkassociates.com.

An investment profile on Exactech may be found at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150910006300/en/